Absci

Absci Cash Conversion Cycle

The Cash Conversion Cycle (CCC) of Absci (ABSI) as of Oct 17, 2026 is -85.67. In the previous year, Cash Conversion Cycle (CCC) was -20.62 — a change of 315.41% (lower).

Cash Conversion Cycle

-85.67

YoY

315.41%

Last updated:

Cash Conversion Cycle (CCC) of Absci is 2025 -85.67 . Cash Conversion Cycle (CCC) of Absci was 2024 -20.62 . It decreases by 315.41% lower compared to the previous year.

The Absci Cash Conversion Cycle history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion Cycle
Date
Cash Conversion Cycle
Jan 1, 2019
-22.69 USD
Jan 1, 2020
-67.47 USD
Jan 1, 2021
17.42 USD
Jan 1, 2022
78.14 USD
Jan 1, 2023
-11.53 USD
Jan 1, 2024
-20.62 USD
Jan 1, 2025
-85.67 USD
The Absci Cash Conversion Cycle history
YEARCash Conversion CycleYoY
-85.67+315.41%
-20.62+78.81%
-11.53-114.76%
78.14+348.54%
17.42-125.82%
-67.47+197.32%
-22.69—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Absci Stock analysis

What does Absci do? Absci Corp, trading under the ticker ABSI with ISIN US00091E1091, is a biotechnology company headquartered in Vancouver, Washington, operating within the Health Care sector. The company went public via an IPO on July 22, 2021. Absci employs 140 people. It leverages artificial intelligence and synthetic biology to explore and expand the therapeutic potential of proteins. The company utilizes a platform combining AI with scalable wet lab technologies to develop biologics for patients. Absci's approach involves identifying novel drug targets, discovering biotherapeutic candidates, and generating cell lines for manufacturing within a single integrated process. The firm applies generative AI to design drug candidates optimized for target affinity, safety, manufacturability, and other characteristics. Absci's technology includes SoluPro, a multiplex synthetic biology method that addresses limitations of high-throughput automation labs. The company supports its AI-driven designs with high-throughput functional validation capabilities in its wet lab. Absci's website is www.absci.com, providing information about its services and technology. The company focuses on creating biologic drug candidates for partners, using data generated from its processes to refine and improve its platform. Absci is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Absci stock

Cash Conversion Cycle (CCC) of Absci is -85.67 in 2025.

Cash Conversion Cycle (CCC) of Absci changed from -20.62 to -85.67, representing a 315.41% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Cycle (CCC) Absci since 2006 – with annual values, charts, and detailed analysis.

The Cash Conversion Cycle measures how long it takes to convert inventory investments into cash from sales. A shorter CCC indicates more efficient working capital management.

CCC = DSO + DIO - DPO

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Cycle (CCC)'s Absci with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Cycle (CCC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Cycle (CCC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Absci

All Key Metrics — Absci